Results 21 to 30 of about 82,153 (256)

Clinical Equipoise for Trials of Novel Biologic Therapies, Therapeutic Success Rates, and Predictors of Success: A Meta-Analysis

, 2017
Purpose The demand for more rapid access to novel biologic therapies than randomized controlled trials can deliver is a topic of ongoing study and debate.
Sarah J. Lord, Johnathan Man, Felicia T. Roncolato, Chee Khoon Lee, John Simes, Doah Cho, Matthew J. Links   +6 more
core   +2 more sources

Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

, 2010
Background: The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve ...
Schmidt Marcus, Hinke Axel, Volkmar Müller, Heilmann Volker, Borowicz, Henryk, Lehnert, Antje, Volker Heilmann, Müller, Volkmar, Axel Hinke, Jackisch, Christian, Möbus, Volker, Christoph Thomssen, Marcus Schmidt, Thomssen, Christoph, Jackisch Christian, Antje Lehnert, Lehnert Antje, Christian Jackisch, Schmidt, Marcus, Glados, Manfred, Heilmann, Volker, Manfred Glados, Volker Möbus, Thomssen Christoph, Henryk Borowicz, Borowicz Henryk, Müller Volkmar, Möbus Volker, Hinke, Axel, Glados Manfred   +29 more
core   +1 more source

Data_Sheet_1_Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis.PDF

, 2020
Background: Several phase-II trials have been designed to evaluate tyrosine kinase inhibitors (TKIs), in particular, pazopanib in neuroendocrine neoplasia (NEN), but its efficacy has not yet been demonstrated in a randomised-controlled Phase III trial. A
Alessandro Vagheggini (5162480), Claudia Cocchi (716745), Chiara Liverani (8678616), Giacomo Miserocchi (8678628), Laura Mercatali (382322), Silvia Nicolini (8678646), Giandomenico Di Menna (8678631), Toni Ibrahim (477361), Alessandro De Vita (8473737), Alberto Bongiovanni (8678613), Valentina Fausti (8678622), Chiara Spadazzi (8678625), Federica Recine (8678619), Stefano Severi (544174)   +13 more
core   +1 more source

Small Interfering RNA (siRNA) of Mini circle DNA Transfection (McD) is Encapsulated by Gold Nanoparticles from Folate’s Receptors of Gold Conjugation as Curative Therapy for Non-Small’s Cell of Lung Cancer

, 2021
Background: Lung cancer is one of the non-communicable diseases that have an increasing number of events that each year with a mortality rate of 18.4% and an incidence of 11.6%, occupies the top position based on GLOBOCAN data in 2018.
indrayani, agung wiwiek, Wiguna, I Gede Wikania Wira, Indrakusuma, Anak Agung Bagus Putra, Wulandari, Putri Ayu, Dewi, Ni Wayan Sucindra, Sadeva, I Gede Krisna Arim, Remitha, Ni Putu Sri Indrani, Sadvika, I Gusti Ayu Sitti   +7 more
core   +2 more sources

Inclusion of elderly patients in oncology clinical trials

, 2016
International audienceBACKGROUND: Physicians need clinical trials assessing benefits and harms of treatments to avoid under-treatment or over-treatment of elderly patients.
Gan, H. K., Freyer, G., Peron, Julien, Falandry, Claire, Le Saux, O., You, Benoit   +5 more
core   +1 more source

Serological Benefit of SARS‐CoV‐2 Vaccination Relative to Infection in Children With Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with acute lymphoblastic leukemia (ALL) are at risk of severe outcomes from SARS‐CoV‐2 (SCV2). In the post‐pandemic context, where most children have been infected with SCV2, there are limited data on whether vaccination remains beneficial in children with ALL.
Janna R. Shapiro, Freda Qi, Karen Colwill, Alina D. Dorogy, Ying Liu, Michelle Science, Anne‐Claude Gingras, James M. Rini, Sumit Gupta, Sarah Alexander, Shelly Bolotin, Tania H. Watts   +11 more
wiley   +1 more source

Advances in PARP Inhibitors for Prostate Cancer

, 2023
Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair. PARPi is a promising drug class that has gained significant traction in the last decade with good outcomes in
Boris Bahoric, Tamim Niazi, Steven Tisseverasinghe, Stephan Probst, Maurice Anidjar   +4 more
core   +1 more source

Heterogeneity in the Global Practice of Central Nervous System Staging in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) involvement in childhood acute lymphoblastic leukemia (ALL) is assessed by cell counting and cytomorphology from cerebrospinal fluid (CSF) and is used for treatment stratification worldwide. The ratio of “CNS2” patients in clinical trials ranges from 3% to 40%, with unclear prognostic significance ...
Laura Almási, Bernadett Borbála Huszti, Gábor Barna, Marko Kavcic, Janez Jazbec, Lennart Lenk, Vera Münch, Sophia Polychronopoulou, Ágnes Márk, Maria Thastrup, Lüder H. Meyer, Kjeld Schmiegelow, Cornelia Eckert, Christina Halsey, Dániel J. Erdélyi   +14 more
wiley   +1 more source

Efficacy and Safety Analysis of Roxarestat in Regulating Renal Anemia in Patients on Maintenance Hemodialysis

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Objective To compare the efficacy and safety of roxarestat versus recombinant human erythropoietin (rhEPO) in the management of renal anemia in patients undergoing maintenance hemodialysis. Methods This was a prospective, open‐label, randomized controlled trial.
Lingling Chen, Junjie Zhu, Qiaonan Ge
wiley   +1 more source

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

, 2015
Recently developed calcitonin gene-related peptide (CGRP) receptor antagonistic molecules have shown promising results in clinical trials for acute treatment of migraine attacks.
Edvinsson, Lars,, Lund University.
core   +2 more sources